- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Retrospective, Multicentre
- Study aim: To assess the real-world use and outcomes of sotrovimab treatment in Belgium among patients with COVID-19 at high risk of developing severe disease
- Number of participants enrolled: 634
- Study enrolling from to
- Study includes follow-up for 29 days
- Standardisation: ICD-10, ATC
Study Data
- Adults
- Elderly
- Fragile population
- Paediatric
- Hospital wide
- Outpatient clinic
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
External Links
Other information
Funders:
- GSK
- Vir Biotechnology
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to